Challenges for taking primary and stem cells into clinical neurotransplantation trials for neurodegenerative disease

Neurobiology of Disease

Volumn 61, Issue , 2014, Pages 79-89

  Dunnett, Stephen B ^a   Rosser, Anne E ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cell therapy; Clean rooms; Clinical trials; Ethics; EU Tissue and Cells directive; Fetal tissues; First in man; GMP; Huntington's disease; Neural transplantation; Parkinson's disease; Regulatory compliance; Stem cells

Indexed keywords

ALEMTUZUMAB; CATECHOLAMINE; DOPAMINE; LEVODOPA; NEUROPROTECTIVE AGENT; SEROTONIN 1A ANTAGONIST; VASOPRESSIN;

ABORTION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTOPSY; BLASTOCYST; BLOOD BRAIN BARRIER; CARCINOGENESIS; CELL ENCAPSULATION; CELL FATE; CELL FUNCTION; CELL GROWTH; CELL MATURATION; CELL PROLIFERATION; CELL PROTECTION; CELL SELECTION; CELL SPECIFICITY; CELL SURVIVAL; CEREBRAL PALSY; CEREBROVASCULAR ACCIDENT; COMMERCIAL PHENOMENA; CONVALESCENCE; COST; DEGENERATIVE DISEASE; DISEASE COURSE; DONOR; DRUG TRANSPORT; DYSKINESIA; EVIDENCE BASED MEDICINE; FETAL TISSUE TRANSPLANTATION; FETUS CELL; GOVERNMENT REGULATION; GRAFT INDUCED DYSKINESIA; GRAFT SURVIVAL; HIV TEST; HUMAN; HUNTINGTON CHOREA; INFORMED CONSENT; MEDICAL ETHICS; MESENCHYMAL STEM CELL; METACHROMATIC LEUKODYSTROPHY; MULTIPLE SCLEROSIS; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NERVE REGENERATION; NEURAL STEM CELL TRANSPLANTATION; NEUROPROTECTION; NEUROSECRETORY CELL; NONHUMAN; PARKINSON DISEASE; PATIENT SAFETY; PLURIPOTENT STEM CELL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECIPIENT; REINNERVATION; REMYELINIZATION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK BENEFIT ANALYSIS; SHY DRAGER SYNDROME; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; STEM CELL RESEARCH; TERMINAL CARE; TRAUMATIC BRAIN INJURY; TREATMENT FAILURE;

CELL THERAPY; CLEAN ROOMS; CLINICAL TRIALS; ETHICS; EU TISSUE AND CELLS DIRECTIVE; FETAL TISSUES; FIRST-IN-MAN; GMP; HUNTINGTON'S DISEASE; NEURAL TRANSPLANTATION; PARKINSON'S DISEASE; REGULATORY COMPLIANCE; STEM CELLS;

CLINICAL TRIALS AS TOPIC; HUMANS; NEURODEGENERATIVE DISEASES; STEM CELL TRANSPLANTATION;

EID: 84888028206     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.05.004     Document Type: Review

References (89)

1. Åkerud P., Canals J.M., Snyder E.Y., Arenas E. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J. Neurosci. 2001, 21:8108-8118.
2. Aubry L., Bugi A., Lefort N., Rousseau F., Peschanski M., Perrier A.L. Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:16707-16712.
3. Bachoud-Lévi A.C., Rémy P., Nguyen J.P., Brugières P., Lefaucheur J.P., Bourdet C., et al. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000, 356:1975-1979.
4. Baker M. Stem-cell pioneer bows out. Nature 2011, 479:459.
5. Bayever E., Ladisch S., Philippart M., Brill N., Nuwer M., Sparkes R.S., et al. Bone-marrow transplantation for metachromatic leucodystrophy. Lancet 1985, 2:471-473.
6. Björklund A., Stenevi U. Neural Grafting in the Mammalian CNS 1985, Elsevier, Amsterdam.
7. Björklund A., Schmidt R.H., Stenevi U. Functional reinnervation of the neostriatum in the adult rat by use of intraparenchymal grafting of dissociated cell suspensions from the substantia nigra. Cell Tissue Res. 1980, 212:39-45.
8. Blakemore W.F. Remyelination of CNS axons by Schwann cells transplanted from the sciatic nerve. Nature 1977, 266:68-69.
9. Boer G.J. Ethical guidelines for the use of human embryonic or fetal tissue for experimental and clinical neurotransplantation and research. J. Neurol. 1994, 242:1-13.
10. Boer G.J., Widner H. Clinical neurotransplantation: core assessment protocol rather than sham surgery as control. Brain Res. Bull. 2002, 58:547-553.
11. Bohn M.C., Cupit L., Marciano F., Gash D.M. Adrenal grafts enhance recovery of striatal dopaminergic fibers. Science 1987, 237:913-916.
12. Bolam J.P., Freund T.F., Björklund A., Dunnett S.B., Smith A.D. Synaptic input and local output of dopaminergic neurons in grafts that functionally reinnervate the host neostriatum. Exp. Brain Res. 1987, 68:131-146.
13. Carroll J.E., Mays R.W. Update on stem cell therapy for cerebral palsy. Expert. Opin. Biol. Ther. 2011, 11:463-471.
14. Chen L., Chen D., Xi H., Wang Q., Liu Y., Zhang F., et al. Olfactory ensheathing cell neurorestorotherapy for amyotrophic lateral sclerosis patients: benefits from multiple transplantations. Cell Transplant. 2012, 21(Suppl. 1):S65-S77.
15. Cheng H., Cao Y.H., Olson L. Spinal cord repair in adult paraplegic rats - partial restoration of hind-limb function. Science 1996, 273:510-513.
16. Cimons M. Bush policy: attention turns to existing human ES cells. Nat. Med. 2001, 7:981-982.
17. Clarke D.J., Dunnett S.B. Synaptic relationships between cortical and dopaminergic inputs and intrinsic GABAergic systems within intrastriatal striatal grafts. J. Chem. Neuroanat. 1993, 6:147-158.
18. David S., Aguayo A.J. Axonal elongation into peripheral nervous system "bridges" after central nervous system injury in adult rats. Science 1981, 214:931-933.
19. Dekkers W., Boer G.J. Sham neurosurgery in patients with Parkinson's disease: is it morally acceptable?. J. Med. Ethics 2001, 27:151-156.
20. Delli Carri A., Onorati M., Castiglioni V., Faedo A., Cattaneo E., Spaiardi P., et al. Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation towards fully functional DARPP-32 positive medium-sized spiny neurons. Development 2013, 140:301-312.
21. Ding X.Q., Bley A., Kohlschutter A., Fiehler J., Lanfermann H. Long-term neuroimaging follow-up on an asymptomatic juvenile metachromatic leukodystrophy patient after hematopoietic stem cell transplantation: evidence of myelin recovery and ongoing brain maturation. Am. J. Med. Genet. 2012, 158A:257-260.
22. Döbrössy M.D., Dunnett S.B. Optimising plasticity: environmental and training associated factors in transplant-mediated brain repair. Rev. Neurosci. 2005, 16:1-21.
23. Dunnett S.B. Neural transplantation. History of Neurology 2010, vol. 95:887-914. Elsevier, Amsterdam & New York, (3rd Series). S. Finger, F. Boller, K. Tyler (Eds.).
24. Dunnett S.B., Björklund A. Mechanisms of function of neural grafts in the adult mammalian brain. J. Exp. Biol. 1987, 132:265-289.
25. Dunnett S.B., Björklund A. Staging and dissection of rat embryos. Neural Transplantation: A Practical Approach 1992, 1-19. IRL Press, Oxford. S.B. Dunnett, A. Björklund (Eds.).
26. Dunnett S.B., Nathwani F., Björklund A. The integration and function of striatal grafts. Prog. Brain Res. 2000, 127:345-380.
27. Dunnett S.B., Björklund A., Lindvall O. Cell therapy in Parkinson's disease - stop or go?. Nat. Rev. Neurosci. 2001, 2:365-369.
28. Editorial ISSCR guidelines for the clinical translation of stem cells. Curr. Protoc. Stem Cell Biol. 2009, (Appendix 1A: Appendix).
29. European Parliament and Council Directive 2004/23/EC of 31 March 2004, on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells. Off. J. Eur. Union 2004, L102:48-58.
30. Evans J.R., Mason S., Barker R.A. Current status of clinical trials of neural transplantation in Parkinson's disease. Prog. Brain Res. 2012, 200:169-198.
31. Falci S., Holtz A., Åkesson E., Azizi M., Ertzgaard P., Hultling C., et al. Obliteration of a posttraumatic spinal cord cyst with solid human embryonic spinal cord grafts: first clinical attempt. J. Neurotrauma 1997, 14:875-884.
32. Fassas A., Kimiskidis V.K., Sakellari I., Kapinas K., Anagnostopoulos A., Tsimourtou V., et al. Long-term results of stem cell transplantation for MS: a single-center experience. Neurology 2011, 76:1066-1070.
33. Folkerth R.D., Durso R. Survival and proliferation of non-neural tissues, with obstruction of cerebral ventricles, in a Parkinsonian patient treated with fetal allografts. Neurology 1996, 46:1219-1225.
34. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 2001, 344:710-719.
35. Freeman T.B., Vawter D.E., Leaverton P.E., Godbold J.H., Hauser R.A., Goetz C.G., et al. Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. N. Engl. J. Med. 1999, 341:988-992.
36. Freeman T.B., Cicchetti F., Bachoud-Lévi A.C., Dunnett S.B. Technical factors that influence neural transplant safety in Huntington's disease. Exp. Neurol. 2011, 227:1-9.
37. Gage F.H., Dunnett S.B., Stenevi U., Björklund A. Aged rats: recovery of motor impairments by intrastriatal nigral grafts. Science 1983, 221:966-969.
38. Gage F.H., Björklund A., Stenevi U., Dunnett S.B., Kelly P.A.T. Intrahippocampal septal grafts ameliorate learning impairments in aged rats. Science 1984, 225:533-536.
39. Gash D.M., Sladek J.R., Sladek C.D. Functional development of grafted vasopressin neurons. Science 1980, 210:1367-1369.
40. Gibson M.J., Krieger D.T., Charlton H.M., Zimmerman E.A., Silverman A.J., Perlow M.J. Mating and pregnancy can occur in genetically hypogonadal mice with preoptic area brain grafts. Science 1984, 225:949-951.
41. Goetz C.G., Stebbins G.T., Klawans H.L., Koller W.C., Grossman R.G., Bakay R.A.E., et al. United Parkinson Foundation neurotransplantation registry on adrenal medullary transplants: presurgical, and 1-year and 2-year follow up. Neurology 1991, 41:1719-1722.
42. Groves A.K., Barnett S.C., Franklin R.J.M., Crang A.J., Mayer M., Blakemore W.F., et al. Repair of demyelinated lesions by transplantation of purified O-2A progenitor cells. Nature 1993, 362:453-455.
43. Guest J.D., Rao A., Olson L., Bunge M.B., Bunge R.P. The ability of human Schwann cell grafts to promote regeneration in the transected nude rat spinal cord. Exp. Neurol. 1997, 148:502-522.
44. Hargraves R.W., Freed W.J. Chronic intrastriatal dopamine infusions in rats with unilateral lesions of the substantia nigra. Life Sci. 1987, 40:959-966.
45. Helm G.A., Palmer P.E., Bennett J.P. Fetal neostriatal transplants in the rat: a light and electron microscopic Golgi study. Neuroscience 1990, 37:735-756.
46. Isacson O., Dunnett S.B., Björklund A. Graft-induced behavioral recovery in an animal model of Huntington disease. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:2728-2732.
47. Jaeger I., Arber C., Risner-Janiczek J.R., Kuechler J., Pritzsche D., Chen I.C., et al. Temporally controlled modulation of FGF/ERK signaling directs midbrain dopaminergic neural progenitor fate in mouse and human pluripotent stem cells. Development 2011, 138:4363-4374.
48. Katsnelson A. Why fake it? How sham brain surgery could be killing off valuable therapies for Parkinson's disease. Nature 2011, 476:142-144.
49. Kiatpongsan S., Sipp D. Medicine. Monitoring and regulating offshore stem cell clinics. Science 2009, 323:1564-1565.
50. Kondziolka D., Wechsler L., Goldstein S., Meltzer C., Thulborn K.R., Gebel J., et al. Transplantation of cultured human neuronal cells for patients with stroke. Neurology 2000, 55:565-569.
51. Kriks S., Shim J.W., Piao J., Ganat Y.M., Wakeman D.R., Xie Z., et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 2011, 480:547-551.
52. Lane E.L., Björklund A., Dunnett S.B., Winkler C. Unraveling the mechanisms underlying graft-induced dyskinesia. Prog. Brain Res. 2010, 184:295-309.
53. Lindvall O. Clinical experiences with dopamine neuron replacement in Parkinson's disease: what is the future?. Dopamine Handbook 2010, 478-488. Oxford University Press, New York. L.L. Iversen, S.D. Iversen, S.B. Dunnett, A. Björklund (Eds.).
54. Lindvall O., Gustavii B., Åstedt B., Lindholm T., Rehncrona S., Brundin P., et al. Fetal dopamine-rich mesencephalic grafts in Parkinson's disease. Lancet 1988, 332:1483-1484.
55. Lindvall O., Brundin P., Widner H., Rehncrona S., Gustavii B., Frackowiak R., et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990, 247:574-577.
56. Luan Z., Liu W., Qu S., Du K., He S., Wang Z., et al. Effects of neural progenitor cell transplantation in children with severe cerebral palsy. Cell Transplant. 2012, 21(Suppl. 1):S91-S98.
57. Ma L., Hu B., Liu Y., Vermilyea S.C., Liu H., Gao L., et al. Human embryonic stem cell-derived GABA neurons correct locomotion deficits in quinolinic acid-lesioned mice. Cell Stem Cell 2012, 10:455-464.
58. Madrazo I., Drucker-Colín R., Díaz V., Martínez-Mata J., Torres C., Becerril J.J. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. N. Engl. J. Med. 1987, 316:831-834.
59. Mamelak A.N., Eggerding F.A., Oh D.S., Wilson E., Davis R.L., Spitzer R., et al. Fatal cyst formation after fetal mesencephalic allograft transplant for Parkinson's disease. J. Neurosurg. 1998, 89:592-598.
60. Martinez-Serrano A., Fischer W., Björklund A. Reversal of age-dependent cognitive impairments and cholinergic neuron atrophy by NGF-secreting neural progenitors grafted to the basal forebrain. Neuron 1995, 15:473-484.
61. Mazzini L., Mareschi K., Ferrero I., Miglioretti M., Stecco A., Servo S., et al. Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study. Cytotherapy 2012, 14:56-60.
62. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 2003, 54:403-414.
63. Olson L., Malmfors T. Growth characteristics of adrenergic nerves in the adult rat. Fluorescence histochemical and 3H-noradrenaline uptake studies using tissue transplantation to the anterior chamber of the eye. Acta Physiol. Scand. Suppl. 1970, 348:1-112.
64. Olson L., Seiger Å., Strömberg I. Intraocular transplantation in rodents: a detailed account of the procedure and examples of its use in neurobiology with special reference to brain tissue grafting. Adv. Cell Neurobiol. 1983, 4:407-442.
65. Perlow M.J., Freed W.J., Hoffer B.J., Seiger Å., Olson L., Wyatt R.J. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 1979, 204:643-647.
66. Pfisterer U., Kirkeby A., Torper O., Wood J., Nelander J., Dufour A., et al. Direct conversion of human fibroblasts to dopaminergic neurons. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:10343-10348.
67. Piccini P., Brooks D.J., Björklund A., Gunn R.N., Grasby P.M., Rimoldi O., et al. Dopamine release from nigral transplants visualised in vivo in a Parkinson's patient. Nat. Neurosci. 1999, 2:1137-1140.
68. Polgar S., Ng J. A critical analysis of evidence for using sham surgery in Parkinson's disease: implications for public health. Aust. N. Z. J. Public Health 2007, 31:270-274.
69. Politis M., Wu K., Loane C., Quinn N.P., Brooks D.J., Rehncrona S., et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci. Transl. Med. 2010, 2:38ra46.
70. Politis M., Wu K., Loane C., Quinn N.P., Brooks D.J., Oertel W.H., et al. Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Sci. Transl. Med. 2012, 4:128ra41.
71. Polkinghorne J., Hoffenberg R., Kennedy I., Macintyre S. Review of the Guidance on the Research Use of Fetuses and Fetal Material 1989, HMSO, London.
72. Quinn N.P. The clinical application of cell grafting techniques in patients with Parkinson's disease. Prog. Brain Res. 1990, 82:619-625.
73. Riley J., Federici T., Polak M., Kelly C., Glass J., Raore B., et al. Intraspinal stem cell transplantation in ALS: a phase I safety trial, technical note and lumbar safety outcomes. Neurosurgery 2012, 71:405-416.
74. Rosenstein J.M., Brightman M.W. Circumventing the blood-brain barrier with autonomic ganglion transplants. Science 1983, 221:879-881.
75. Rosser A.E., Bachoud-Lévi A.C. Clinical trials of neural transplantation in Huntington's disease. Prog. Brain Res. 2012, 200:245-271.
76. Sandberg P.R., Eve D.J., Metcalf C., Borlongan C. Advantages and challenges of alternative sources of adult-derived stem cells for brain repair in stroke. Prog. Brain Res. 2012, 201.
77. Schmidt R.H., Björklund A., Stenevi U. Intracerebral grafting of dissociated CNS tissue suspensions: a new approach for neuronal transplantation to deep brain sites. Brain Res. 1981, 218:347-356.
78. Schwartz S.D., Hubschman J.P., Heilwell G., Franco-Cardenas V., Pan C.K., Ostrick R.M., et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 2012, 379:713-720.
79. Seledtsov V.I., Rabinovich S.S., Parlyuk O.V., Kafanova M.Y., Astrakov S.V., Seledtsova G.V., et al. Cell transplantation therapy in re-animating severely head-injured patients. Biomed. Pharmacother. 2005, 59:415-420.
80. Siatskas C., Payne N.L., Short M.A., Bernard C.C. A consensus statement addressing mesenchymal stem cell transplantation for multiple sclerosis: it's time!. Stem Cell Rev. 2010, 6:500-506.
81. Sinden J.D., Vishnubhatla I., Muir K.W. Prospects for stem cell-derived therapy in stroke. Prog. Brain Res. 2012, 201:117-165.
82. Sladek J.R., Gash D.M. Neural Transplants, Development and Function 1984, Plenum Press, New York.
83. Sotelo C., Alvarado-Mallart R.M. Embryonic and adult neurons interact to allow Purkinje cell replacement in mutant cerebellum. Nature 1987, 327:421-423.
84. Stenevi U., Björklund A., Svendgaard N.-A. Transplantation of central and peripheral monoamine neurons to the adult rat brain: techniques and conditions for survival. Brain Res. 1976, 114:1-20.
85. Tan S.A., Aebischer P. The problems of delivering neuroactive molecules to the CNS. CIBA Found. Symp. 1996, 196:211-236.
86. Thompson W.G. Successful brain grafting. N. Y. Med. J. 1890, 51:701-702.
87. Wahlberg L.U., Lind G., Almqvist P.M., Kusk P., Tornoe J., Juliusson B., et al. Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery. J. Neurosurg. 2012, 117:340-347.
88. Xu Z.C., Wilson C.J., Emson P.C. Synaptic potentials evoked in spiny neurons in rat neostriatal grafts by cortical and thalamic stimulation. J. Neurophysiol. 1991, 65:477-493.
89. Zhou X.H., Ning G.Z., Feng S.Q., Kong X.H., Chen J.T., Zheng Y.F., et al. Transplantation of autologous activated Schwann cells in the treatment of spinal cord injury: six cases, more than five years of follow-up. Cell Transplant. 2012, 21(Suppl. 1):S39-S47.